48 LONGEVITY
compared to untreated skin, when combined with 1% Eterwell Youth, as predicted, it boosted collagen production by an impressive 200%. Despite being one of the most challenging
signs of ageing to address, because pores become larger and more visible as collagen levels fall, both pore number and pore volume were also included in the study. Pores enlarge as we age, and this can
be clearly seen in the images taken over a lifetime shown in Figure 3. While pores can be considered as just another sign of ageing alongside wrinkles and fine lines, in some populations, particular in Asian communities, they actually take precedence over wrinkles as the main indicators of age. Pore size and volume were measured using the images taken during the clinical trial (Figure 4). The test product with Palmitoyl Tripeptide-5
alone produced significant improvement in pore number and volume (-7% and -8% respectively), when compared to the untreated skin. However, as with collagen density, these improvements were boosted when 1.5% Palmitoyl Tripeptide-5 was combined with 1% Eterwell Youth. Again, remarkably, the inclusion of the senolytic doubled the efficacy. The striking improvements achieved by
combining 1.5% Palmitoyl Tripeptide-5 with 1.0% Eterwell Youth compared to both untreated skin and skin treated with Palmitoyl Tripeptide-5 alone is captured in the advanced Antera 3D® imaging shown in Figure 5. Clearly, at four weeks and even more
impressively, after eight weeks these troubling signs of ageing had been significantly reduced, and the volunteers skin looks healthier. The combination of active and senolytic,
also doubled the efficacy of the other characteristics (forehead wrinkles and crow’s feet) measured in the study. Looking at the results for Palmitoyl Tripeptide-5 alone, where some parameters plateaued after initial improvement, it might be that senescent cells partially destroy the active and/or the newly synthesised collagen, acting as biological roadblocks, creating cellular resistance that limits traditional actives’ effectiveness. However, the breakthrough discovery lies in
the synergistic relationship between senolytic and peptide active. Across every parameter measured this combination consistently delivered approximately double the improvement compared to the peptide alone. Senescent cell clearance unlocks the
peptide’s full regenerative power, transforming limited responses into sustained, progressive improvements. This validates the pioneering approach of using senolytics to maximizes conventional skin care ingredients’ long-term efficacy.
Conclusion The beauty industry’s transformation from anti- ageing to skin longevity represents more than just a shift in terminology. It is a fundamental change in how we approach skincare. It plugs into skin biology for targeted, effective, personalized solutions. While the development of senolytic technology like Eterwell Youth marks an
PERSONAL CARE November 2025 BASELINE 4 WEEKS 8 WEEKS
Figure 5: Antera 3D® images showing the effects of 1.5% Palmitoyl Tripeptide-5 alone and in combination with 1% Eterwell Youth on one volunteer’s Pore size and volume
important advancement in cellular science, the most significant breakthrough lies in the discovery that senolytics can dramatically enhance the performance of traditional skin care ingredients. Today, clinical evidence shows that
senolytic compounds can double the efficacy of established actives—such as collagen-boosting peptides—by amplifying their impact on the main visible signs of ageing. By removing the biological roadblocks that limit conventional actives’ effectiveness, senolytic-enhanced formulations represent the future of evidence- based skin care. As the industry continues to embrace this holistic, science-driven approach, consumers can expect increasingly sophisticated solutions and truly personalised advanced skin care that does not just address the visible signs of ageing but actively support skin’s long-term health and resilience. This is the promise of skin longevity, not the impossible pursuit of perfection, but the achievable goal of looking and feeling your best throughout life.
References 1. Voegeli R, Schoop R, Prestat-Marquis E, Rawlings AV, Shackelford TK, Fink B. Differences between perceived age and chronological age in women: A multi-ethnic and multi-centre study. International
Journal of Cosmetic Science. 2021; 43(5), 547-560
2. Hussein RS, Bin Dayel S, Abahussein O, El- Sherbiny AA. Influences on Skin and Intrinsic Aging: Biological, Environmental, and Therapeutic Insights. J Cosmet Dermatol. 2025; Feb;24(2):e16688
3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023 Jan 19;186(2):243-278
4. Tenchov R, Sasso JM, Wang X, Zhou QA. Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement. ACS Chem Neurosci. 2024 Jan 3;15(1):1-30
5. Guo J, Huang X, Dou L et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Sig Transduct Target Ther. 2022; 7, 391
PC
6. Dodig S, Čepelak I, Pavić I. Hallmarks of senescence and aging. Biochem Med (Zagreb). 2019; Oct 15;29(3):030501
7. Sun Y, Li Q, Kirkland JL. Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging. Life Med. 2022; Aug 9;1(2):103-119
8. Dorf N, Maciejczyk M. Skin senescence-from basic research to clinical practice. Front Med (Lausanne). 2024 ;Oct 18;11:1484345
www.personalcaremagazine.com
1% Eterwell Youth + 1.5% SYN®-COLL CB Volunteer 4 Cheek left (age 52)
Skin Antera images BASELINE
1.5% Syn-Coll CB Volunteer 4 Cheek right (age 52)
4 WEEKS
8 WEEKS
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107
